Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2–2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepato-splenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5–25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population.
LazzarottoTGuerraBGabrielliLLanariMLandiniMP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect2011; 17(9):1285–93.
2.
CollOBenoistGVilleYWeismanLEBotetFAnceschiMMGreenoughAGibbsRS. Guidelines on CMV congenital infection. J Perinat Med2009; 37(5):433–45.
3.
SharlandMLuckSGriffithsPCottonM. Antiviral therapy of CMV disease in children. Adv Exp Med Biol2011; 697:243–60.
4.
SchleissMR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol2008; 325:361–82.
5.
GriffithsPDMcLeanAEmeryVC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine2001; 19(11–12):1356–62.
6.
EmeryVC. Could a vaccine against immuneevading cytomegalovirus become a reality?Expert Rev Vaccines2011; 10(8): 1109–11.
7.
NyholmJLSchleissMR. Prevention of maternal cytomegalovirus infection: Current status and future prospects. Int J Womens Health2010; 2:23–35.
8.
JacobsonMASinclairEBredtB. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine2006; 24(25):5311–9.
9.
HeinemanTCSchleissMBernsteinDI. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis2006; 193(10): 1350–60.
10.
AxelssonFAdlerSPLamarreAOhlinM. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine2007; 26(1):41–6.
11.
SchleissMR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr2007; 151(6):564–70.
12.
PassRFZhangCEvansA. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med2009; 360(12):1191–9.
13.
SabbajSPassRFGoepfertPAPichonS. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis2011; 203(11): 1534–41.
14.
GriffithsPDStantonAMcCarrellE. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet2011; 377(9773): 1256–63.
15.
GeniniEPercivalleESarasiniARevelloMGBaldantiFGernaG. Serum antibody response to the gH/gL/pUL 128–131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol2011; 52(2): 113–8.
16.
GönczölEBerensciKPincusSEndreszVMéricCPaolettiEPlotkinSA. Preclinical evaluation of an ALVAC (canarypox)–human cytomegalovirus glycoprotein B vaccine candidate. Vaccine1995; 13(12):1080–5.
17.
BerencsiKGyulaiZGönczölE. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis2001; 183(8): 1171–9.
18.
BernsteinDIReapEAKatenK. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine2009; 28(2):484–93.
19.
WangZZhouWSrivastavaTLa RosaCMandarinoAFormanSJZaiaJABrittWJDiamondDJ. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology2008; 377(2):379–90.
20.
ZhaoPMaDYanSShaoNZhangJBiZDaiJJiMJiC. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope. Intervirology2009; 52(1):35–42.
21.
ShanleyJDWuCA. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine2005; 23(8):996–1003.
22.
ZhongJKhannaR. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases. J Clin Virol2009; (S):S68–72.
23.
BenMohamedLKrishnanRLongmateJAugeCLowLPrimusJDiamondDJ. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: Dependence on HLA class II restricted T(H) response. Hum Immunol2000; 61(8):764–79.
24.
GopalINQuinnAHenrySCHamiltonJDStaatsHFFrothinghamR. Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. Microbiol Immunol2005; 49(2): 113–9.
25.
La RosaCLongmateJLaceySF. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and Tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis2012; 205(8): 1294–304
26.
TempertonNJ. DNA vaccines against cytomegalovirus: Current progress. Int J Antimicrob Agents2002; 19(3): 169–72.
27.
SelinskyCLukeCWlochMGeallAHermansonGKaslowDEvansT. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin2005; 1(1):16–23.
28.
YueYKaurAEberhardtMKKassisNZhouSSTarantalAFBarryPA. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65–2, and viral interleukin-10 in rhesus macaques. J Virol2007; 81(3): 1095–109.
29.
SlavuljicaIBuscheABabićM. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest2010; 120(12):4532–45.
30.
WlochMKSmithLRBoutsaboualoyS. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis2008; 197(12): 1634–42.
31.
Kharfan-DabajaMABoeckhMWilkMB. A Novel therapeutic cytomegalovirus DNA vaccine in allogenic haemopoietic stem-cell transplantation: A randomized, double blind, placebo-controlled, phase 2 trial. Lancet Infection Dis2012; 12:290–99.
32.
ShenSWangSBrittWJLuS. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine2007; 25(17):3319–27.
33.
Pepperl-KlindworthSFrankenbergNPlachterB. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol2002; 25(S):S75–85.
34.
LogsdonNJEberhardtMKAllenCEBarryPAWalterMR. Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus. PLoS One2011; 6(11):e28127.
35.
DhuruvasanKSivasubramanianGPellettPE. Roles of host and viral microRNAs in human cytomegalovirus biology. Virus Res2011; 157(2): 180–92
36.
MitchellDKHolmesSJBurkeRLDuliegeAMAdlerSP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J2002; 21(2): 133–8.
PettyTJCallahanSTChenQEdwardsKMDempseyAF. Assessment of parental acceptance of a potential cytomegalovirus vaccine for adolescent females. Vaccine2010; 28(35):5686–90.
